Pfizer Efficacy - Search News

Pfizer’s Lyme vaccine shows efficacy

Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal.

· 2d · on MSN

Pfizer, Valneva report strong efficacy data from Lyme vaccine trial

· 3h

Lyme disease vaccine trial results 'encouraging' after more than 70% efficacy shown, doctors say

· 1d

Pfizer Lyme Disease Vaccine Shows 70% Efficacy, But Misses Statistical Goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal.

· 19h

Pfizer’s Lyme Vaccine Misses Mark in Study, Complicating Quest for Approval

· 2d

Pfizer says Lyme disease vaccine is holding promise

2hon MSN

Is Pfizer stock a buy after this win?

Good news has been scarce for this beaten-down drugmaker.

7hon MSN

Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA®

Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on March 19 positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA®,